Psyomics has raised $11.0M in total across 4 funding rounds.
Psyomics's investors include ACF Investors, Parkwalk Advisors.
Psyomics is a health technology company specializing in digital mental health assessment tools designed to improve the accuracy, efficiency, and accessibility of mental health diagnosis and triage. Its flagship product, Censeo, is a digital platform that enables patients to complete comprehensive mental health questionnaires at their own pace, providing clinicians with structured data and rich patient narratives to support more informed treatment decisions. Psyomics serves healthcare providers, particularly within the NHS in the UK, therapists, and mental health services, addressing the challenge of lengthy and inconsistent mental health assessments. By automating and standardizing intake processes, Psyomics increases clinical capacity and helps patients access the right level of care more quickly, demonstrating strong growth momentum with expanding NHS partnerships and recent funding rounds[1][2][4][5].
Founded in March 2015 by Professor Sabine Bahn, a practicing psychiatrist and neurotechnology expert at the University of Cambridge, and Dan Cowell, Psyomics emerged from academic research at the Cambridge Centre for Neuropsychiatric Research. The company was created to leverage digital and biomarker technologies to improve psychiatric diagnostics and patient outcomes. Early development involved extensive clinical trials with over 5,000 participants, resulting in a sophisticated branching questionnaire system with more than 1,700 questions. This research-driven foundation and collaboration with clinicians helped Psyomics gain early traction, particularly within NHS mental health services, where it has since expanded its reach and product offerings, including solutions for neurodiversity and young people[3][4][5].
Psyomics rides the growing trend of digital transformation in mental health care, addressing critical market forces such as rising mental health awareness, increasing demand on healthcare systems, and the need for scalable, precise diagnostic tools. The timing is crucial as mental health services face capacity constraints and seek to move from analogue to digital processes. Psyomics influences the ecosystem by providing tools that enhance clinical efficiency, reduce misdiagnosis, and promote personalized care pathways. Its integration of digital assessments with biomarker research positions it at the forefront of precision psychiatry, contributing to a broader shift towards data-driven, patient-centered mental health care[1][2][3][4].
Looking ahead, Psyomics is poised to expand its impact by scaling its digital platform across more NHS trusts and entering new markets, including the US, supported by recent funding and regulatory progress such as FDA engagement for its neurodiversity assessment platform. Trends shaping its journey include the increasing adoption of digital health tools, advances in biomarker diagnostics, and growing demand for personalized mental health care. Psyomics’ influence is likely to grow as it continues to bridge clinical expertise with technology, potentially setting new standards for mental health assessment and treatment worldwide. This aligns with its mission to revolutionize mental health diagnostics, ensuring patients receive timely, accurate, and tailored care from the very first contact[2][4][6][7].
Psyomics has raised $11.0M across 4 funding rounds. Most recently, it raised $5.0M Venture Round in June 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2024 | $5.0M Venture Round | ACF Investors, Parkwalk Advisors | |
| Jan 1, 2022 | $3.0M Venture Round | ACF Investors, Parkwalk Advisors | |
| Oct 1, 2020 | $2.0M Venture Round | ACF Investors, Parkwalk Advisors | |
| Jun 1, 2016 | $1.0M Series A | ACF Investors, Parkwalk Advisors |
